TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00085631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperthermia treatment
Description: Patients undergo hyperthermia treatment over 60-90 minutes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Patients undergo brachytherapy for 2-3 days

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: brachytherapy
Description: Patients undergo brachytherapy for 2-3 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Patients undergo external beam radiation therapy once daily on days 1-5

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy
Description: Patients undergo external beam radiation therapy once daily on days 1-5
Study: NCT01788332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 100mg tablets to be administered twice a day with approximately 240ml of water
Study: NCT03571815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish
Description: application of sodium fluoride varnish on teeth

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WATER ON TEETH
Description: control group
Study: NCT02058667

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Initial Radiation+Boost
Description: Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
Study: NCT04404374

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A-PRF/EMD
Description: Comparing healing effect of an autologous and a xenogenic product

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A-PRF/EMD
Description: Comparing healing effect of an autologous and a xenogenic product
Study: NCT00545194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin E2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin E2
Study: NCT02692703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glecaprevir/pibrentasvir
Description: Tablet; glecaprevir coformulated with pibrentasvir
Study: NCT04779840

Intervention type: OTHER
Intervention: anemia assessment
Description: evaluation of anemia status

Intervention type: OTHER
Intervention: anemia assessment
Description: evaluation of anemia status
Study: NCT00495339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 500-1000 mg once a day daily per os with combination of drugs.
Study: NCT01925053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAL meal
Description: The effect of consuming the PAL meal on gastric retention will be assessed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: REF meal
Description: The effect of consuming the REF meal on gastric retention will be assessed
Study: NCT00321802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Patients take 40 mg of simvastatin per day for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00025766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with stenting
Description: PCI with stenting of the occluded culprit infarct-related artery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy
Description: Participants will receive optimal medical therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Participants will receive optimal medical therapy.
Study: NCT02170298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisdexamfetamine
Description: Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
Study: NCT03414814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 MG [Tagrisso]
Description: Osimertinib 80mg once daily until disease progression
Study: NCT04107194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40mg
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1000 MG
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 MG
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline 125 MG
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline 125 MG
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Subcitrate
Description: Antibiotic adjuvant
Study: NCT01216709

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous sulfate
Description: 6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron-fortified infant formula (12.4 mg iron/L)
Description: 6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron-fortified infant formula (2.3 mg iron/L)
Description: 1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
Study: NCT01343186

Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa
Description: s,c, 45mcg of Ypeginterferon alfa-2a

Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa 2a
Description: s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.

Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa-2a
Description: s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.

Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa-2a
Description: s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
Study: NCT03299205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
Study: NCT04107194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Subcitrate
Description: Antibiotic adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin 150 MG
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: Antibiotic
Study: NCT03854682

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Non-surgical treatment consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
Study: NCT05346926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed cast
Description: The 3D-printed casts are produced using 3D print technology based on software by Belgian software company: The patient's forearm is scanned with a tablet (duration: approx. 5 min), whereupon the cast is printed overnight according to the scan (duration: approx. 4h) and adjusted to the patient during the next appointment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cast
Description: A conventional plaster cast is applied for treatment of the distal radius fracture.
Study: NCT03651830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic Foot Emulator
Description: Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available prosthetic feet
Description: Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet.
Study: NCT03501316

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Instrumentation Treatment
Description: Provision of treatment for periodontal disease using hand instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic Instrumentation Treatment
Description: Provision of treatment for periodontal disease using ultrasonic instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
Study: NCT02944968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL SMARTTOUCH® SF-5D catheter
Study: NCT02315001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: GLP-1 receptor agonist administered via subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume-matched normal saline placebo administered via subcutaneous injection
Study: NCT03071770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivosidenib (AG-120)
Description: A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
Study: NCT02556814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeic acid tablets
Description: Oral administration of caffeic acid tablets 0.3g three times per day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral administration of placebo tablets 0.3g three times per day for 3 months
Study: NCT00652405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alcohol
Description: 250 ml of white wine (13% vol; \~25 gram of alcohol per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 ml of mineral water (Brand name: Vittel)
Study: NCT04115748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily with or without food
Study: NCT02101060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 16-week progressive aerobic and resistance exercise training
Study: NCT02269241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LF111 (drospirenone)
Description: One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
Study: NCT04229394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2ccPA
Description: Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1
Study: NCT04115748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily with or without food
Study: NCT04229394

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1
Study: NCT02254486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trisulfate solution
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
Study: NCT03556150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy protocol
Description: This protocol consists of:~* Six minutes of joint's mobilisation (two minutes of each technique).~* Nine minutes of ischemic pressure . Three minutes per muscle in this order: temporal muscle, masseter muscle and lateral pterygoid. Choosing the two most painful trigger points.~* Three minutes of trigemino's nerve stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effleurage
Description: The protocol consists of:~* Five minutes in temporal muscle.~* Ten minutes superficial massage in the neck and cheek of the most painful joint.~* Five minutes of effleurage in the cheek, with the index finger inside the mouth and the thumb outside.
Study: NCT02254187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol capsule - low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol capsule - high

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol via Serevent® Diskus®
Study: NCT01427504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir; etravirine
Description: boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
Study: NCT01427504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir; etravirine
Description: boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir; etravirine
Description: boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir; etravirine
Description: boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
Study: NCT04115748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Injection administered subcutaneously once every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food
Study: NCT01885195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
Study: NCT04204291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
Study: NCT03277118

Intervention type: DEVICE
Intervention: Wireless Wearable Device
Description: Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
Study: NCT04362839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT04115748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food
Study: NCT04544449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenebrutinib
Description: Participants will receive fenebrutinib.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Participants will receive ocrelizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to ocrelizumab
Description: Participants will receive ocrelizumab-matching placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matched to fenebrutinib
Description: Participants will receive fenebrutinib-matching placebo
Study: NCT04492033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-009 (ABL001)
Description: CTX-009 (ABL001) will be administered biweekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-009 (ABL001)
Description: CTX-009 (ABL001) will be administered biweekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-009 (ABL001)
Description: CTX-009 (ABL001) will be administered biweekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered biweekly.
Study: NCT03566043

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-121
Description: Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-121
Description: Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-121
Description: Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-121
Description: Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-121
Description: Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-121
Description: Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
Study: NCT02542605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered once on day 1 of Part B of the study by intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once on day 1 of Part B of the study by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACAP-38 Challenge Agent
Description: Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.
Study: NCT02263989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan film coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan conventional tablet
Study: NCT02811250

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy 4 x 8 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy 5 x 8 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy 4 x 10 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy 4 x 12 Gy